CCM
MRSN

Consonance Capital Management’s Mersana Therapeutics MRSN Stock Holding History

Consonance Capital Management’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-56,068
Closed -$37.3M – 41
2020
Q4 		$37.3M Sell
56,068
-82,659
-60% -$46M 3.48% 12
2020
Q3 		$64.6M Sell
138,727
-97,126
-41% -$49.1M 7.87% 3
2020
Q2 		$138M Buy
+235,853
New +$80.5M 8.27% 1

Other funds holding MRSN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Consonance Capital Management's MRSN Position: Q1 2021 in Review

Consonance Capital Management sold out of Mersana Therapeutics (MRSN) in Q1 2021, closing a stake of 56,068 shares — an estimated $37.3M sold.

Consonance Capital Management first reported a position in MRSN in Q2 2020 and held it in 3 quarters. The position peaked at $138M in Q2 2020. 132 funds tracked by Wall St. Rank hold MRSN as of Q1 2021.

  • Consonance Capital Management reported no remaining Mersana Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Consonance Capital Management sold 56,068 Mersana Therapeutics shares in Q1 2021, an estimated $37.3M.
  • Consonance Capital Management first reported a position in Mersana Therapeutics in Q2 2020 and held it in 3 quarters.
  • Consonance Capital Management's Mersana Therapeutics position peaked at $138M in Q2 2020.
  • 132 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2021.

Based on Consonance Capital Management's 13F filing for Q1 2021, filed 17 May 2021.